Maintenance rucaparib has proven to be a safe and effective maintenance option for PALB2 PV/LPV patients, in addition to BRCA1/2, with platinum-sensitive advanced pancreatic cancer in a phase 2 trial, and it is a current FDA approved-indication [44]. Here, BRCA1 is linked to familial pancreatic carcinoma.